medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2024, Number 3

<< Back Next >>

Rev Nefrol Dial Traspl 2024; 44 (3)

The usefulness of parathyroid ultrasound in the diagnosis and definition of the treatment of secondary hyperparathyroidism in patients with chronic renal disease in dialytic therapy

Restrepo VCA, Cárdenas JE, Chacón CJA

Language: Spanish
References: 44
Page: 133-141
PDF size: 189.91 Kb.


ABSTRACT

Introduction: Secondary hyper parathyroidism is a common complication in patients with chronic kidney disease (CKD). Objective: The objective of this study was to evaluate by imaging (neck ultrasound and parathyroid scintigraphy) patients with CKD on dialysis therapy with PTH values higher than the optimal recommended by the KDIGO guidelines in order to establish whether it was present in them with higher frequency the presence of nodular parathyroid hyperplasia, which could change its therapeutic approach. Materials and methods: This type of study is descriptive, observational, and retrospective from a single center. Patients with chronic kidney disease on dialysis therapy were included, and bone and mineral disorders were characterized by PTH values greater than 600 pg/ml, in whom anthropometric and laboratory variables were available. The included patients underwent ultrasound and parathyroid scintigraphy and were classified into three groups depending on the detection of images suggestive of parathyroid adenomas. Results: 653 patients with CKD on dialysis therapies were evaluated. PTH higher than 600 pg/ml was detected in 117 (17.9%). In 65 (55.56%), no images compatible with adenomas were detected (Group 1); in 52 (44.44%), adenomas were detected, dividing into 38 (32.48%) with adenomas smaller than 1000 mm3 (Group 2). ), and 14 (11.97%) with an adenoma larger than 1000 mm3 (Group 3). Group 3 had a longer time on dialysis and significantly higher values of calcium, alkaline phosphatase, and PTH. Conclusions: Nodular hyperplasia of the parathyroid glands can affect a significant number of patients with CKD on dialysis therapy, in whom the PTH value is higher than 600 pg/ml. Its detection and evaluation of the number and volume of adenomas could guide the nephrologist in proposing the best therapeutic option for them.


REFERENCES

  1. KDIGO 2017 Clinical Practice Guideline Update forthe Diagnosis, Evaluation, Prevention, and Treatmentof Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD). Kidney Int Suppl.2017;7:1–59.

  2. Reiss A B, Miyawaki N, Moon J, Kasselman LJ,Voloshyna I, D´Avino R et al. CKD, arterialcalcification, atherosclerosis and bone health: Interrelationshipsand controversies. Atherosclerosis.2018;278: 49–59

  3. Tominaga Y, Takagi H. Molecular genetics ofhyperparathyroid disease. Curr Opin Nephrol Hypert1996; 5: 336-341

  4. Cunningham J, Locatelli F, Rodriguez M. Secondaryhyperparathyroidism: pathogenesis, disease progression,and therapeutic options. Clin J Am Soc Nephrol 2011;6:913-921

  5. Tominaga Y, Tanaka Y, Sato K, Nagasaka T, TakagiH. Histopathology, pathophysiology, and indicationsfor surgical treatment of renal hyperparathyroidism.Semin. Surg. Oncol. 1997; 13:78–86

  6. Tominaga Y, Matsuoka S, Sato K, Uno N, Goto N,Katayama A, et al. Clinical features and hyperplasticpatterns of parathyroid glands in hemodialysis patientswith advanced secondary hyperparathyroidismrefractory to maxacalcitol treatment and requiredparathyroidectomy. Ther Apher Dial 2007; 11:266–273

  7. Restrepo VCA, Santacruz PD, Castillo PCE, CaconCJA. Detección de hiperplasia de paratiroides porultrasonografía y correlación con signos clínicos y delaboratorio en pacientes con enfermedad renal crónica.Rev Colomb Radiol 2011: 22: 3341-3347

  8. Restrepo CA, Castillo CE, Sanz MF. Aplicación seriadade paricalcitol intranodular ¿Es eficaz en el tratamientodel hiperparatiroidismo secundario refractario? ActaMed Colomb 2015; 40: 125-131

  9. Restrepo VCA, Castillo CE, Sanz MF, Velez C. Laeficacia del etanol intraglandular en hiperparatiroidismosecundario se limita a una sola glándula hiperplásica.Acta Med Colomb 2013; 38: 61-67

  10. Sanint V, Restrepo VCA, Chala GAI. Experienciacon paratiroidectomía quirúrgica en pacientes conenfermedad renal crónica e hiperparatiroidismoterciario. Acta Med Colomb 2018; 43: 136-141

  11. KDIGO clinical practice guideline for the diagnosis,evaluation, prevention, and treatment of chronickidney disease-Mineral and Bone Disorder (CKDMBD).Kidney Int 2009; 76(suppl 113):S1-S130

  12. Giangrande A, Castiglioni A, Solbiati L, Allaria P.Ultrasound-guided percutaneous fine-needle ethanolinjection into parathyroid glands in secondaryhyperparathyroidism. Nephrol Dial Transplant. 1992;7:412–421

  13. Parfitt AM. The hyperparathyroidism of chronic renalfailure: a disorder of growth. Kidney Int 1997; 52: 3–9.

  14. Drueke TB. Cell biology of parathyroid glandhyperplasia in chronic renal failure. J Am Soc Nephrol2000; 11: 1141–1152

  15. Moela M, Petruci I, Calliada F, Barsotti W, Puccin M, etal. Presurgical setting of secondary hyperparathyroidismusing high-resolution sonography and color Doppler.Ultraschall in Med 2011; 32: S74 – S82.

  16. Ribeiro C, Moreira MG, Moreira MM, Sousa TM,Neves SB, Ferreira LA, et al. World J Nephrol 2016; 5:437-447.

  17. Gwiasda J, Kaltenbor A, Mullar JA, Serttas M,Scheumann GF, Schrem H, et al. . Langenbecks Arch,Surg 2017;402:295-301

  18. 18) Onoda N, Kurihara S, Sakurai Y, Owada K, OsonoE, Adachi H, et al. Evaluation of blood supply to theparathyroid glands in secondary hyperparathyroidismcompared with histopathology. Nephrol Dial Transplant2003; 18 [Suppl 3]: iii34–iii37.

  19. Katoh N, Nakayama M, Shigematsu T, YamamotoH, Sano K, Saito I, et al. Presence of sonographicallydetectable parathyroid glands can predict resistanceto oral pulsed-dose calcitriol treatment of secondaryhyperparathyroidism. Am J Kidney Dis 2000; 35:465-468.

  20. Fukagawa M, Kitaoka M, Yi H, Fukuda N, MatsumotoT, Ogata E, et al. Serial evaluation of parathyroid size byultrasonography is another useful marker for the longtermprognosis of calcitriol pulse therapy in chronicdialysis patients. Nephron 1994; 68: 221–228.

  21. Fukagawa M, Kitaoka M, Yi H, Fukuda N,Matsumoto T, Ogata E, Kurokawa K. Serial evaluationof parathyroid size by ultrasonography is another usefulmarker for the long-term prognosis of calcitriol pulsetherapy in chronic dialysis patients. Kidney Int Suppl1997; 62:S60–S64.

  22. Okuno S, Ishimura E, Kitatani K, Chou H, NagasueK, Maekawa K, et al. Relationship between parathyroidgland size and responsiveness to maxacalcitol therapy inpatients with secondary hyperparathyroidism. NephrolDial Transplant 2003; 18: 2613-2621

  23. Tominaga Y, Inaguma D, Matsuoka S, Tahara H,Kukita K, Kurihara S, et al. Is the volume of theparathyroid gland a predictor of Maxacalcitol responsein advanced secondary hyperparathyroidism? TherApher Dial 2006; 10: 198-204.

  24. Tominaga Y, Matsuoka S, Sato T, Uno N, Goto N,Katayama A, et al. Clinical features and hyperplasticpatterns of parathyroid glands in hemodialysis patientswith advanced secondary hyperparathyroidismrefractory to maxacalcitol treatment and requiredparathyroidectomy. Ther Apher Dial 2007; 11: 266-273.

  25. Tanaka M, Nakanishi S, Komaba H, Itoh K,Matsushita K, Fukagawa M. Association betweenlong-term efficacy of cinacalcet and parathyroidgland volume in haemodialysis patients withsecondary hyperparathyroidism. NDT Plus 2008; 1Suppl 3: iii49-iii53

  26. Hirai T, Nakashima A, Takasugi N, Yorioka N.Association of nodular hyperplasia with resistance tocinacalcet therapy for secondary hyperparathyroidismin hemodialysis patients. Ther Apher Dial 2010; 14:577-582.

  27. Yamamoto M, Ogata H, Mizobuchi M, Yoshida N,Kumata-Maeta C, Koiwa F, et al. Number of enlargedparathyroid glands might be a predictor of cinacalcetresponse in advanced secondary hyperparathyroidism.Clin Exp Nephrol 2012; 16: 292-299,

  28. Hong YA, Cho YS, Kim SW, Jung MY, Lee EA, KoGJ, et al. Diameter of parathyroid glands measuredby computed tomography as a predictive indicatorfor response to cinacalcet in dialysis patients withsecondary hyperparathyroidism. Kidney Blood PressRes 2015; 40: 277-287.

  29. Hirai T, Nakashima A, Takasugi N, Yorioka N.Response of Secondary Hyperparathyroidism toCinacalcet Depends on Parathyroid Size. Nephron ClinPract 2010; 114:c187–c193.

  30. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, KKurokawa, Y Seino. Decreased 1,25-dihydroxyvitaminD3 receptor density is associated with a more severeform of parathyroid hyperplasia in chronic uremicpatients. J Clin Invest 1993; 92: 1436-1443

  31. Tokumoto M, Tsuruya K, Fukuda K, Kanai H,Kuroki S, Hirakata H. Reduced p21, p27 and vitaminD receptor in the nodular hyperplasia in patients withadvanced secondary hyperparathyroidism. Kidney Int2002; 62: 1196-1207.

  32. Gogusev J, Duchambon P, Hory B, Giovannini M,Goureau Y, Sarfati E, et al. Depressed expressionof calcium receptor in parathyroid gland tissue ofpatients with hyperparathyroidism. Kidney Int 1997;51:328-336.

  33. Restrepo CA, Lopez GG, Musso CG. Evidencia dehiperplasia multinodular de paratiroides en un pacientecon enfermedad renal crónica. Rev Colomb EndocrinolDiabet Metab 2021; 8: e692.

  34. Kakuta T, Tanaka R, Kanai G, Miyamoto Y, InagakiM, Suzuki H, et al. Relationship between theweight of parathyroid glands and their secretion ofparathyroid hormone in hemodialysis patients withsecondary hyperparathyroidism. Ther Apher Dial2008; 12: 385-390.

  35. Matsuoka S, Tominaga Y, Sato T, Uno N, HiramituT, Goto N, et al. Relationship between the dimensionof parathyroid glands estimated by ultrasonographyand the hyperplastic pattern in patients with renalhyperparathyroidism. Ther Apher Dial 2008; 12:391-395.

  36. Fang L, Tang B, Hou D, Meng M, Xiong M, Yang J.Relationship between parathyroid mass and parathyroidhormone level in hemodialysis patients with secondaryhyperparathyroidism. BMC Nephrology 2015; 16: 82.

  37. Jäger MD, Serttas M, Beneke J, Müller JA, SchremH, Kaltenborn A, et al. Risk-factors for nodularhyperplasia of parathyroid glands in sHPT patients.Plos ONE 2017; 12: E0186093,

  38. Gwiasda J, Kaltenborn A, Müller JA, Serttas M,Scheumann GWF, Schrem H, et al. Ultrasound-basedscores as predictors for nodular hyperplasia in patients withsecondary hyperparathyroidism: a prospective validationstudy. Langenbecks Arch Surg 2017; 402:295-301.

  39. Vulpio C, Bossola M, Gaetano A, Maresca G,Di Stasio E, Spada PL, et al. Ultrasound patterns ofparathyroid glands in chronic hemodialysis patients withsecondary hyperparathyroidism. Am J Nephrol 2008; 28:589-597.

  40. Meola M, Petrucci I, Calliada F, Barsotti M,Puccini M, Grosso M, et al. Presurgical setting ofsecondary hyperparathyroidism using high-resolutionsonography and color Doppler. Ultraschall in Med 2011;32: S74 – S82.

  41. Vulpio C, Bossola M, Magalini SC, SilvestriP, Fadda G, Ciliberti M, et al. Parathyroid-glandultrasonography in clinical and therapeutic evaluation ofrenal secondary hyperparathyroidism. Radiol Med 2013;118:707-722.

  42. Ribeiro C, Moreira MG, Moreira MM, TavaresMS, Souza BN, Leite AF, et al. Parathyroid ultrasonographyand bone metabolic profile of patients on dialysis withhyperparathyroidism. World J Nephrol 2016; 5: 437-447.

  43. Zhang X, Xu W, Huang T, Huang J, Zhang C,Zhang Y, et al. The value of clinical-ultrasonographicfeature model to predict the severity of secondaryhyperparathyroidism. Renal Failure 2022; 44: 146-154.

  44. Rivera G M, Sosa B R H, Ruiz-Zorrilla L C,Fernández JM, Marrero R S, Ibeas L J, la at. Documento deconsenso para la formación en ecografía en la especialidadde Nefrología. Nefrologia 2020;40(6):623–633.




2020     |     www.medigraphic.com